Antibody therapies against both are currently being tested in clinical trials for cancer31,32,39,40, and a blocking antibody against IL-6 is FDA approved to treat rheumatoid arthritis and acute cytokine release syndrome, a side effect of CAR-T cell therapy33. The gene discussed is IL6; the disease is rheumatoid arthritis.